Satsuma Pharma

News

FDA resurrects Satsuma's nasal migraine treatment

More than a year after it was rejected by the FDA, Satsuma Pharma's intranasal migraine therapy Atzumi has been given the go-ahead by the agency.

News

FDA turns down Satsuma’s nasal migraine treatment

Manufacturing problems have scuppered Satsuma Pharmaceuticals’ chances of a timely FDA approval for its intranasal migraine therapy STS101.

News

Satsuma pulped as acute migraine drug flunks phase 3 trial

Shares in California biotech Satsuma Pharma have lost three quarters of their value after lead drug STS01 failed to show any improvement over placebo in an acute migraine study.

FDA resurrects Satsuma's nasal migraine treatment

FDA turns down Satsuma’s nasal migraine treatment

Satsuma pulped as acute migraine drug flunks phase 3 trial

Chiesi signs $1.9bn deal to buy KalVista and its HAE drug

Using AI-driven synthetic personas to take your insights fur...

Editor's Picks